Plain-English translation of NCT06596954 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Esophageal squamous cell cancer is a serious disease, and doctors currently treat it with chemotherapy, radiation, and surgery. This trial is testing a new way to deliver radiation therapy that aims to protect your body's lymphocytes—the immune cells that help fight cancer and infections. The hope is that by protecting these important cells during treatment, patients may have better outcomes and fewer cancer recurrences.
Even with current treatments, about half of patients with advanced esophageal cancer experience cancer coming back or spreading. Recent research suggests that radiation therapy can damage the immune system by killing lymphocytes, which may make it harder for your body to fight remaining cancer cells. This trial wants to find out whether protecting these immune cells during radiation could improve survival and reduce recurrence.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new immune-sparing radiation therapy or standard radiation therapy, along with chemotherapy before surgery. The main difference is that the new approach uses special planning to limit radiation dose to certain areas where immune cells are concentrated, while still treating your cancer effectively. Your participation involves receiving the planned radiation and chemotherapy, undergoing surgery, and having follow-up visits to monitor your health and cancer status over time.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China